Sleep Apnoea vs COPD — Clinical Trial Comparison
Sleep Apnoea
Repeated breathing pauses during sleep
COPD
Progressive airflow limitation from airway damage
Sleep apnoea and COPD are both common respiratory conditions, and they frequently overlap (overlap syndrome affects 10–15% of COPD patients). While sleep apnoea is characterised by upper airway collapse during sleep, COPD involves permanent lung damage from chronic inflammation. Their trial landscapes differ significantly — sleep apnoea trials focus on CPAP alternatives and metabolic outcomes, while COPD trials test inhaled therapies and anti-inflammatory approaches.
Key Differences at a Glance
| Feature | Sleep Apnoea | COPD |
|---|---|---|
| Primary mechanism | Upper airway collapse during sleep | Permanent airflow limitation from lung damage |
| Key symptom | Loud snoring, daytime sleepiness, witnessed apnoeas | Chronic cough, sputum, breathlessness on exertion |
| Diagnostic test | Polysomnography or home sleep study (AHI score) | Spirometry (FEV1/FVC ratio < 0.7) |
| Common subtypes | Obstructive (OSA), central (CSA), mixed | Chronic bronchitis, emphysema, AATD-related |
| UK prevalence | ~1.5 million diagnosed (many more undiagnosed) | ~1.2 million diagnosed |
| NICE first-line | CPAP therapy, weight management | Inhaled bronchodilators + corticosteroids |
Clinical Trial Availability
| Trial Aspect | Sleep Apnoea | COPD |
|---|---|---|
| UK trials actively recruiting | 25–45 studies | 30–50 studies |
| Most common trial phase | Phase 2–3 | Phase 2–3 |
| Top interventions tested | CPAP alternatives, hypoglossal nerve stimulation, weight loss drugs, positional therapy | Novel bronchodilators, anti-inflammatory agents, pulmonary rehabilitation, stem cell therapy |
| Device trials | Major category (nerve stimulation, oral appliances, CPAP tech) | Moderate (inhaler tech, oxygen delivery, non-invasive ventilation) |
| Metabolic/cardiovascular outcomes | Major focus (BP, diabetes, cardiac risk) | Growing focus (cardiovascular comorbidity) |
| Overlap syndrome trials | Emerging | Emerging |
Exciting Emerging Treatments
Sleep Apnoea Trials
- Hypoglossal nerve stimulation — implantable device preventing airway collapse
- GLP-1 receptor agonists — weight loss improving OSA severity (semaglutide trials)
- Positional therapy devices — preventing supine sleep without CPAP
- Upper airway surgery innovations — drug-induced sleep endoscopy-guided procedures
- Digital CPAP optimisation — AI-driven pressure adjustment and adherence tracking
- Pharmacological treatments — first drug therapies targeting OSA mechanisms directly
COPD Trials
- Novel anti-inflammatory agents — targeting specific inflammatory pathways in COPD
- Stem cell therapy — regenerative approaches for emphysema and lung damage
- Alpha-1 antitrypsin augmentation — gene therapy and replacement for AATD-related COPD
- Triple inhaler optimisation — improving delivery and adherence of LABA/LAMA/ICS combinations
- Pulmonary rehabilitation technology — remote monitoring and VR-based exercise programmes
- Biomarker-driven therapy — eosinophil-guided treatment selection
💡 Overlap syndrome means you might qualify for both
About 10–15% of COPD patients also have sleep apnoea (overlap syndrome). This combination worsens outcomes significantly. If you have COPD and experience daytime sleepiness, morning headaches, or your partner notices breathing pauses during sleep, ask about a sleep study. Overlap syndrome is increasingly targeted by clinical trials.
Eligibility Differences
Sleep Apnoea Trial Criteria
- Confirmed OSA diagnosis with AHI ≥ 5 (moderate-severe trials require AHI ≥ 15)
- CPAP intolerance or refusal for alternative therapy trials
- BMI thresholds common (some require BMI ≥ 30, others < 40 for surgical trials)
- Cardiovascular screening often required (ECG, BP monitoring)
- Exclusion of central sleep apnoea and neuromuscular conditions
- Home sleep study may be acceptable for screening in some trials
COPD Trial Criteria
- Confirmed COPD diagnosis with spirometry (FEV1/FVC < 0.7)
- Severity stratification by FEV1 (% predicted): mild, moderate, severe, very severe
- Smoking status matters — some trials require current smokers, others ex-smokers only
- Exacerbation history commonly required (≥ 2 moderate or ≥ 1 severe in past year)
- Alpha-1 antitrypsin testing for certain COPD subtypes
- Concurrent asthma diagnosis may be exclusionary (ACO is separate category)
😴 Sleep Apnoea Trials
Find actively recruiting sleep apnoea clinical trials across the UK
View Sleep Apnoea Trials